Stifel cuts argenx stock price target on mixed quarter results
Stifel reduced its price target for argenx (NASDAQ:ARGX) to $1,200 from $1,282, citing mixed Q3 2026 results. Vyvgart sales beat estimates, but a Sjogren’s trial was discontinued. The company reported 70% revenue growth over the last year. Analysts remain bullish on its pipeline, with price targets ranging from $823 to $1,356.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short-term selling but long-term upside remains if upcoming trials succeed.
Market read
Analyst target reduction provides a fresh catalyst for traders to reassess ARGX positioning.
What to watch
Positive Vyvgart sales and upcoming data could offset short-term downside.
Background
Stifel analysts revised ARGX valuation after mixed quarterly performance, including a trial discontinuation and strong sales.
Ticker impact
Stifel cut ARGX price target to $1,200 from $1,282 after mixed Q3 results and trial setbacks.
likely downside pressure as investors price in lower expectations
Analyst downgrade with a lower price target typically leads to short-term sell pressure.
Market effects
Biotech sector may see modest pullback as a peer's target is reduced.
Limited to US-listed biotech investors.
Low global impact.
Counterpoint
Target cut may be overly cautious given strong revenue growth and pipeline progress.
Key entities
- companyargenx SE
Biotech firm developing immunology drugs.
- analystStifel
Equity research firm issuing the price target cut.
